Drug Profile
Bevacizumab biosimilar - Nanogen Biopharmaceutical
Latest Information Update: 12 Jan 2022
Price :
$50
*
At a glance
- Originator Nanogen Biopharmaceutical Co
- Class Antineoplastics; Eye disorder therapies; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Apr 2018 No recent reports of development identified for research development in Cancer in Vietnam (IV, Infusion)
- 21 Mar 2014 Early research in Cancer in Vietnam (IV)